AIM AIM ImmunoTech (AIM) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0000946644
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
9
13F, latest reported quarter
What the filings say about AIM
Insiders, 180 days
+$23.6K net bought
1 buyer
AIM ImmunoTech insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, AIM ImmunoTech Inc. insiders bought a net $23.6K of stock across 41 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 26 earlier Form 4 trades (code P or S) here by this insider (26 buys), the last on Oct 22, 2026.
- -30.0% median (-12.3% mean) 90-day return after 19 previous buys.
- The trade is 16.7% of the 189,747 shares held after it.
- No other insider bought within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO & President Equels Thomas K bought about $5.1K of AIM on Oct 23, 2026; 9 funds added in the latest 13F quarter.Context
- 25 earlier Form 4 trades (code P or S) here by this insider (25 buys), the last on Sep 17, 2026.
- -30.0% median (-12.3% mean) 90-day return after 19 previous buys.
- The trade is 19.8% of the 158,072 shares held after it.
- No other insider bought within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO & President Equels Thomas K bought about $5.1K of AIM on Oct 22, 2026, the largest insider purchase at the company since 2025; 9 funds added in the latest 13F quarter.Context
- 24 earlier Form 4 trades (code P or S) here by this insider (24 buys), the last on Sep 16, 2026.
- -30.0% median (-12.3% mean) 90-day return after 19 previous buys.
- The trade is 18.9% of the 126,822 shares held after it.
- No other insider bought within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO & President Equels Thomas K bought about $5.0K of AIM on Sep 17, 2026, the largest insider purchase at the company since 2025; 9 funds added in the latest 13F quarter.Context
- 23 earlier Form 4 trades (code P or S) here by this insider (23 buys), the last on Sep 15, 2026.
- -30.0% median (-12.3% mean) 90-day return after 19 previous buys.
- The trade is 10.7% of the 102,822 shares held after it.
- No other insider bought within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO & President Equels Thomas K bought about $2.3K of AIM on Sep 16, 2026; 9 funds added in the latest 13F quarter.Context
- 22 earlier Form 4 trades (code P or S) here by this insider (22 buys), the last on Sep 14, 2026.
- -30.0% median (-12.3% mean) 90-day return after 19 previous buys.
- The trade is 24.0% of the 91,822 shares held after it.
- No other insider bought within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO & President Equels Thomas K bought about $4.9K of AIM on Sep 15, 2026, the largest insider purchase at the company since 2025; 9 funds added in the latest 13F quarter.41 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$23.6K over 180 days
+$23.6K over 90 days
more than 70% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
9 funds bought in last quarter
below 86% of Pharma & Biotech
Revenue
-48.2% year over year
below 79% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
5.1% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 51% of Pharma & Biotech
What changed in the last 30 days
Oct 26CEO & President Equels Thomas K bought $10.2K (2 trades, Oct 22 to Oct 23)
Watch AIM
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-93.3%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns AIM: institutional holders (13F)
13F holdings, latest reported quarter
807,885 sh
$229.4K
50,864 sh
$14.4K
46,003 sh
$13.1K
32,444 sh
$9.2K
28,931 sh
$8.2K
Congress trades in AIM
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
AIM planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
AIM mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$11.4K position · as of 2026-05-31
0.0%
Fidelity Series Total Market Index Fund
$278 position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
3 registered trials, 0 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
2
Phase 2
0 active
1
Not applicable
0 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Thomas K. Equels
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$640.2K
$640.2K
$246.0K
-96%
n/a
2024
$1.1M
$1.1M
$285.9K
-36%
n/a
2023
$1.4M
$1.5M
$369.9K
+42%
n/a
2022
$1.4M
$1.2M
$332.1K
-66%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $23.6K bought by insiders over 180 days, 9 funds added last quarter. Each figure is a federal filing, dated the day it went public.
AIM financials
Revenue growth
-48.2%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$95.0K
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM AIM
| FY Dec 2025 | $88.0K |
| FY Dec 2024 | $170.0K |
| FY Dec 2023 | $202.0K |
| FY Dec 2022 | $140.0K |
| FY Dec 2021 | $134.0K |
| Jun 2026 | $26.0K |
| Mar 2026 | $22.0K |
| Dec 2025 | $21.0K |
| Sep 2025 | $26.0K |
| Jun 2025 | $25.0K |
| Mar 2025 | $16.0K |
| Dec 2024 | $45.0K |
| Sep 2024 | $35.0K |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Net margin, TTM AIM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
Free cash flow, TTM AIM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -$4.0M |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
0.47x
LongTermDebt as filed 2026-06-30 (includes the current portion); equity 2026-06-30
Debt to equity AIM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 0.20x |
| FY Dec 2022 | 0.05x |
| FY Dec 2021 | 0.04x |
| Jun 2026 | 0.47x |
| Mar 2026 | 1.98x |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | 0.94x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-3.97x
TTM operating cash flow over LongTermDebt as filed 2026-06-30 (includes the current portion)
Cash flow to debt AIM
| FY Dec 2025 | -2.45x |
| FY Dec 2024 | -5.30x |
| FY Dec 2023 | -10.37x |
| FY Dec 2022 | -7.86x |
| FY Dec 2021 | -6.81x |
| Jun 2026 | -3.97x |
| Mar 2026 | -2.69x |
| Dec 2025 | -2.45x |
| Sep 2025 | -4.75x |
| Jun 2025 | -4.03x |
| Mar 2025 | -5.21x |
| Dec 2024 | -5.30x |
| Sep 2024 | -7.57x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-2,382%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity AIM
| FY Dec 2025 | n/a |
| FY Dec 2024 | -388.7% |
| FY Dec 2023 | -118.9% |
| FY Dec 2022 | -40.8% |
| FY Dec 2021 | -32.4% |
| Jun 2026 | -2,382% |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | -3,139% |
| Dec 2024 | -388.7% |
| Sep 2024 | -187.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-169.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets AIM
| FY Dec 2025 | -194.0% |
| FY Dec 2024 | -123.8% |
| FY Dec 2023 | -96.8% |
| FY Dec 2022 | -39.6% |
| FY Dec 2021 | -31.3% |
| Jun 2026 | -169.3% |
| Mar 2026 | -179.0% |
| Dec 2025 | -194.0% |
| Sep 2025 | -165.1% |
| Jun 2025 | -162.9% |
| Mar 2025 | -135.6% |
| Dec 2024 | -123.8% |
| Sep 2024 | -115.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital AIM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-1,465%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed AIM
| FY Dec 2025 | n/a |
| FY Dec 2024 | -403.4% |
| FY Dec 2023 | -128.0% |
| FY Dec 2022 | -41.4% |
| FY Dec 2021 | -31.3% |
| Jun 2026 | -1,465% |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | -589.9% |
| Jun 2025 | -5,455% |
| Mar 2025 | -1,264% |
| Dec 2024 | -403.4% |
| Sep 2024 | -209.7% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
16.62x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing AIM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 28.00x |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
-$1.2M
market value at close 2026-10-27 on 2026-08-07 shares, plus LongTermDebt as filed 2026-06-30 (includes the current portion), minus cash 2026-06-30
Enterprise value AIM
| FY Dec 2025 | $4.6M |
| FY Dec 2024 | $1.2B |
| FY Dec 2023 | $2.1B |
| FY Dec 2022 | $1.4B |
| FY Dec 2021 | $4.2B |
| Jun 2026 | -$2.2M |
| Mar 2026 | $3.2M |
| Dec 2025 | $4.6M |
| Sep 2025 | $7.6M |
| Jun 2025 | $643.4M |
| Mar 2025 | $842.9M |
| Dec 2024 | $1.2B |
| Sep 2024 | $1.5B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
FCF yield AIM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
PEG, trailing AIM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $88.0K | $170.0K | $202.0K | $141.0K |
| Operating income | -$11.7M | -$19.8M | -$31.9M | -$19.9M |
| Net income | -$14.0M | -$17.3M | -$29.0M | -$19.4M |
| EPS (diluted) | -8.62 | -30.92 | -0.60 | -0.40 |
| Operating cash flow | -$11.0M | -$14.9M | -$21.3M | -$16.1M |
| Cash | $3.0M | $1.7M | $5.4M | $27.1M |
| Long-term debt | $927.0K | $2.8M | n/a | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
AIM Stock Sonar score 6/7 axes
Find similar shapesCompareAIM ranks highest on risk and compliance (75th percentile) and insider conviction (62nd), and lowest on profitability (5th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
AIM filings, in plain words
Are AIM ImmunoTech insiders buying or selling AIM?
In the 180 days to 2026-10-28, AIM ImmunoTech insiders were net buyers, a net $23.6K across purchases and sales reported on Form 4, by 1 buyer.
Read the full summary
In the 180 days to 2026-10-28, AIM ImmunoTech insiders were net buyers of AIM, a net $23.6K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
